100 related articles for article (PubMed ID: 28453877)
41. Does Reducing Basal Insulin During Ramadan Fasting by Children and Adolescents with Type 1 Diabetes Decrease the Risk of Symptomatic Hypoglycemia?
Deeb A; Al Qahtani N; Attia S; Al Suwaidi H; Nagelkerke N
Diabetes Technol Ther; 2016 Sep; 18(9):539-42. PubMed ID: 27500913
[TBL] [Abstract][Full Text] [Related]
42. Explorative study of pharmacokinetics and pharmacodynamics after change in basal insulin infusion rate.
Ihlo CA; Lauritzen T; Sturis J; Skyggebjerg O; Christiansen JS; Laursen T
J Diabetes Sci Technol; 2011 Jan; 5(1):120-8. PubMed ID: 21303634
[TBL] [Abstract][Full Text] [Related]
43. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin.
; Tsalikian E; Kollman C; Tamborlane WB; Beck RW; Fiallo-Scharer R; Fox L; Janz KF; Ruedy KJ; Wilson D; Xing D; Weinzimer SA
Diabetes Care; 2006 Oct; 29(10):2200-4. PubMed ID: 17003293
[TBL] [Abstract][Full Text] [Related]
44. The time lag prior to the rise in glucose requirements to maintain stable glycaemia during moderate exercise in a fasted insulinaemic state is of short duration and unaffected by the level at which glycaemia is maintained in Type 1 diabetes.
Shetty VB; Fournier PA; Davey RJ; Retterath AJ; Paramalingam N; Roby HC; Davis EA; Jones TW
Diabet Med; 2018 Oct; 35(10):1404-1411. PubMed ID: 29939421
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes.
Svehlikova E; Ashcroft NL; Gatschelhofer C; Gerring D; Höller V; Jezek J; Lackner B; Lawrence F; Pillai V; Ratzer M; Urschitz M; Wolf M; Pieber TR
Diabetes Care; 2023 Apr; 46(4):757-764. PubMed ID: 36710473
[TBL] [Abstract][Full Text] [Related]
46. Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Kildegaard J; Buckley ST; Nielsen RH; Povlsen GK; Seested T; Ribel U; Olsen HB; Ludvigsen S; Jeppesen CB; Refsgaard HHF; Bendtsen KM; Kristensen NR; Hostrup S; Sturis J
Pharm Res; 2019 Feb; 36(3):49. PubMed ID: 30746556
[TBL] [Abstract][Full Text] [Related]
47. Establishing Methods to Determine Clinically Relevant Bolus and Basal Rate Delivery Accuracy of Insulin Pumps.
Kamecke U; Waldenmaier D; Haug C; Ziegler R; Freckmann G
J Diabetes Sci Technol; 2019 Jan; 13(1):60-67. PubMed ID: 30003823
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection.
Engwerda EEC; Tack CJ; de Galan BE
J Diabetes Sci Technol; 2017 Sep; 11(5):947-952. PubMed ID: 28303726
[TBL] [Abstract][Full Text] [Related]
49. Prospective External Validation of an Algorithm Predicting Hourly Basal Insulin Infusion Rates from Characteristics of Patients with Type 1 Diabetes Treated with Insulin Pumps.
Schmelzer JS; Kahle-Stephan M; Meier JJ; Nauck MA
Exp Clin Endocrinol Diabetes; 2023 Oct; 131(10):539-547. PubMed ID: 37473769
[TBL] [Abstract][Full Text] [Related]
50. Comparative dose accuracy of durable and patch insulin infusion pumps.
Jahn LG; Capurro JJ; Levy BL
J Diabetes Sci Technol; 2013 Jul; 7(4):1011-20. PubMed ID: 23911184
[TBL] [Abstract][Full Text] [Related]
51. The future of care for type 1 diabetes.
Nathan DM; Russell S
CMAJ; 2013 Mar; 185(4):285-6. PubMed ID: 23359043
[No Abstract] [Full Text] [Related]
52. Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy.
Nauck MA; Kahle-Stephan M; Lindmeyer AM; Wenzel S; Meier JJ
J Diabetes Sci Technol; 2021 Nov; 15(6):1273-1281. PubMed ID: 33251851
[TBL] [Abstract][Full Text] [Related]
53. Occlusion Detection Time in Insulin Pumps at Two Different Basal Rates.
Freckmann G; Kamecke U; Waldenmaier D; Haug C; Ziegler R
J Diabetes Sci Technol; 2018 May; 12(3):608-613. PubMed ID: 29284290
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes.
Haidar A; Elleri D; Kumareswaran K; Leelarathna L; Allen JM; Caldwell K; Murphy HR; Wilinska ME; Acerini CL; Evans ML; Dunger DB; Nodale M; Hovorka R
Diabetes Care; 2013 Oct; 36(10):e173-4. PubMed ID: 24065849
[No Abstract] [Full Text] [Related]
55. Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion.
Ziegler R; Oliver N; Waldenmaier D; Mende J; Haug C; Freckmann G
Diabetes Technol Ther; 2021 May; 23(5):350-357. PubMed ID: 33210949
[No Abstract] [Full Text] [Related]
56. Absorption of subcutaneously infused insulin: influence of the basal rate pulse interval.
Hildebrandt P; Birch K; Jensen BM; Kühl C; Brange J
Diabetes Care; 1985; 8(3):287-9. PubMed ID: 3891269
[TBL] [Abstract][Full Text] [Related]
57. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps.
Schaepelynck Bélicar P; Vague P; Lassmann-Vague V
Diabetes Metab; 2003 Sep; 29(4 Pt 1):344-8. PubMed ID: 14526262
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart.
Mansell EJ; Schmidt S; Docherty PD; Nørgaard K; Jørgensen JB; Madsen H
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):477-489. PubMed ID: 28831695
[TBL] [Abstract][Full Text] [Related]
59. Subcutaneous insulin infusion: change in basal infusion rate has no immediate effect on insulin absorption rate.
Hildebrandt P; Birch K; Jensen BM; Kühl C
Diabetes Care; 1986; 9(6):561-4. PubMed ID: 3542448
[TBL] [Abstract][Full Text] [Related]
60. Pitfalls of insulin pump clocks: technical glitches that may potentially affect medical care in patients with diabetes.
Aldasouqi SA; Reed AJ
J Diabetes Sci Technol; 2014 Nov; 8(6):1215-20. PubMed ID: 25355713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
